Role of Antibodies Against Glutamate Receptors and Double Stranded DNA in Epilepsy Patients

NCT00317668 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2007-05-01

No results posted yet for this study

Summary

The investigators will check the serum of epilepsy patients for antibodies against glutamate receptors and double stranded DNA. They will characterise the patients (by the kind of epilepsy, autoimmune disease comorbidity, and cognitive profile).

Conditions

Sponsors & Collaborators

  • Hadassah Medical Organization

    lead OTHER

Principal Investigators

  • Dana Ekstein, MD · Hadassah Medical Organization

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-11-30

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00317668 on ClinicalTrials.gov